The Effect of Royal Jelly on Irisin in Experimentally Diabetic Rats

Yıl 2023, Cilt: 27 Sayı: 4, 912 - 919, 25.08.2023

Selcen Çakır

https://doi.org/10.16984/saufenbilder.1256089

Cited By: 2

Öz

Diabetes Mellitus (DM) is considered a very common health problem today. It causes many acute and chronic complications and negatively affects the quality of life of patients. It is known that diabetes has an impact on many biochemical processes. This study aimed to evaluate the interaction between royal jelly (RJ) and diabetes with irisin, a parameter that has not been investigated before. The study was planned with 3 groups: control group, DM group, DM+350 mg/kg RJ group. In the experiments, 18 female Wistar albino rats were studied. Irisin levels in rat blood serum were determined using the ELISA (Enzyme-Linked Immuno Sorbent Assay) method. Glucose levels in blood taken from the tail vein were determined with a glucometer. As a result of the experimental study, a statistically significant difference was found in the DM+350 mg/kg RJ group compared to the control group (p<0.05). The selected dose reduced serum irisin levels in RJ applications. With diabetes, a statistically significant increase was observed in blood glucose levels (p<0.05). Although the RJ application caused a numerical decrease, it was not statistically significant. Previous studies have emphasized the effect of RJ on DM and blood biochemical parameters; however, the observation that the relevant dose of RJ reduces irisin levels is recent. The relationship of irisin with energy metabolism is still being investigated. Further studies are required to explain the relationship between irisin and RJ.

Anahtar Kelimeler

Diabetes mellitus, Irisin, Royal jelly

Kaynakça

• H. Duan, B. Ma, X. Ma, H. Wang, Ni Z, Wang B, Li X, Jiang P, Umar M, M. Li, "Anti-diabetic activity of recombinant irisin in STZ-induced insulin-deficient diabetic mice," International Journal of Biological Macromolecules, vol.84, pp 457-63, 2016.
• P, Boström, J. Wu, MP. Jedrychowski , A. Korde, L. Ye, JC. Lo, KA. Rasbach, Boström EA, JH. Choi, JZ. Long, Kajimura S, Zingaretti MC, Vind BF, Tu H, Cinti S, Højlund K, SP. Gygi, BM. Spiegelman, "PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis," Nature, vol. 481, pp 463-8, 2012.
• S. Shen, Q. Liao, X.Chen, C. Peng, Lin L, "The role of irisin in metabolic flexibility: Beyond adipose tissue browning. Drug Discovery Today,"vol. 27, no. 8, pp 2261-7, 2022.
• A. Roca-Rivada,C. Castelao, LL. Senin, MO. Landrove, J. Baltar, AB Crujeiras, LM. Seoane, FF. Casanueva, M. Pardo, "FNDC5/Irisin Is Not Only a Myokine but Also an Adipokine," PLoS One,vol. 8, no. 4, pp 1-10, 2013.
• HP. Erickson, "Irisin and FNDC5 in retrospect," Adipocyte,vol. 2, no.4, pp 289-93, 2013.
• L. Huang, S. Yan, L. Luo, L. Yang, "Irisin regulates the expression of BDNF and glycometabolism in diabetic rats," Molecular Medicine Reports, vol. 19, no. 2, pp 1074-82, 2019.
• Liu Y, F. Xu, P. Jiang, "Effect of sitagliptin on expression of skeletal muscle peroxisome proliferator-activated receptor γ coactivator-1α and irisin in a rat model of type 2 diabetes mellitus," Journal of International Medical Research, vol. 48, no.5, 2020.
• N. Perakakis, GA. Triantafyllou, JM. Fernández-Real, JY. Huh, KH. Park, J. Seufert, CS. Mantzoros, "Physiology and role of irisin in glucose homeostasis," Nature Reviews Endocrinology, vol. 13, no. 6, pp 324-37, 2017.
• E. Ghanbari, V. Nejati, M. Khazaei, "Antioxidant and protective effects of Royal jelly on histopathological changes in testis of diabetic rats," International Journal of Reproductive BioMedicine, vol. 14, no. 8, pp 511-8, 2016.
• M. Yoshida, K. Hayashi, R. Watadani, Y. Okano, K. Tanimura, J. Kotoh, D. Sasaki, K. Matsumoto, A. Maeda, "Royal jelly improves hyperglycemia in obese/diabetic KK-Ay mice," Journal of Veterinary Medical Science, vol. 79, no. 2, pp 299-307, 2017.
• A. Stocker, P. Schramel, A. Kettrup, E. Bengsch, "Trace and mineral elements in royal jelly and homeostatic effects," Journal of Trace Elements in Medicine and Biology, pp 183-9, 2005.
• K. Tokunaga hiko, C. Yoshida, Suzuki K michi, H. Maruyama, Y. Futamura, Y. Araki, S. Mishima, "Antihypertensive effect of peptides from Royal Jelly in spontaneously hypertensive rats," Biological and Pharmaceutical Bulletin, vol. 27, no. 2, pp 189-92, 2004.
• H. Guo, A. Saiga, M. Sato, I. Miyazawa, M. Shibata, Y. Takahata, F. Morimatsu, "Royal jelly supplementation improves lipoprotein metabolism in humans," Journal of Nutritional Science and Vitaminology, vol. 53, no. 4, pp 345-8, 2007.
• E. Ghanbari, V. Nejati, M, Khazaei, "Improvement in serum biochemical alterations and oxidative stress of liver and pancreas following use of royal jelly in streptozotocin-induced diabetic rats," Cell Journal, vol. 18, no. 3, pp 362-70, 2016.
• N. Marrano, G. Biondi, A. Borrelli, A. Cignarelli, S. Perrini, L. Laviola, F. Giorgino, A. Natalicchio. "Irisin and incretin hormones: Similarities, differences, and implications in type 2 diabetes and obesity," Biomolecules, vol. 11, pp 1-23, 2021.
• H. Li, F. Wang, M. Yang, J. Sun, Y. Zhao, D. Tang. "The Effect of Irisin as a Metabolic Regulator and Its Therapeutic Potential for Obesity," International Journal of Endocrinology, 2021.
• C. Malfitano, A.L. de Souza Junior, M. Carbonaro, A. Bolsoni-Lopes, D. Figueroa, L.E. de Souza, K.A.S. Silva, F. Consolim-Colombo, R. Curi, M.C. Irigoyen, "Glucose and fatty acid metabolism in infarcted heart from streptozotocin-induced diabetic rats after 2weeks of tissue remodeling," Cardiovascular Diabetology, vol. 14, pp 1-10, 2015.
• M.R. Alezandro, D. Granato, M.I. Genovese, "Jaboticaba (Myrciaria jaboticaba (Vell.) Berg), a Brazilian grape-like fruit, improves plasma lipid profile in streptozotocin-mediated oxidative stress in diabetic rats," Food Research International, vol. 54, pp 650-659, 2013.
• S. Jiang, L. Piao, E.B. Ma, H. Ha, J.Y. Huh, "Associations of circulating irisin with fndc5 expression in fat and muscle in type 1 and type 2 diabetic mice," Biomolecules, vol. 11, pp 1-14, 2021. X.Q. Xiong, D. Chen, H.J. Sun, L. Ding, J.J. Wang, Q. Chen, Y.H. Li, Y.B. Zhou, Y. Han, F. Zhang, X.Y. Gao, Y.M. Kang, G.Q. Zhu, "FNDC5 overexpression and irisin ameliorate glucose/lipid metabolic derangements and enhance lipolysis in obesity," Biochimica et Biophysica Acta - Molecular Basis of Disease, vol. 1852 pp 1867-1875, 2015.
• Y.K. Choi, M.K. Kim, K.H. Bae, H.A. Seo, J.Y. Jeong, W.K. Lee, J.G. Kim, I.K. Lee, K.G. Park, "Serum irisin levels in new-onset type 2 diabetes, Diabetes Res," Diabetes Research and Clinical Practice, vol. 100, pp 96-101, 2013. J.M. Moreno-Navarrete, F. Ortega, M. Serrano, E. Guerra, G. Pardo, F. Tinahones, W. Ricart, J.M. Fernández-Real, "Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance," Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 4, pp 769-778, 2013.
• M.G. Hekim, M.M. Kelestemur, F.G. Bulmus, B. Bilgin, F. Bulut, E. Gokdere, M.R. Ozdede, H. Kelestimur, S. Canpolat, M. Ozcan, "Asprosin, a novel glucogenic adipokine: a potential therapeutic implication in diabetes mellitus," Arch. Physiol. Biochem, pp 1-7, 2021.
• F. Norheim, T.M. Langleite, M. Hjorth, T. Holen, A. Kielland, H.K. Stadheim, H.L. Gulseth, K.I. Birkeland, J. Jensen, C.A. Drevon, "The effects of acute and chronic exercise on PGC-1α, irisin and browning of subcutaneous adipose tissue in humans," FEBS Journal, vol. 281, no. 3, pp 739-749, 2014. N.M. Al-Daghri, M.S. Alokail, S. Rahman, O.E. Amer, O.S. Al-Attas, H. Alfawaz, G. Tripathi, S. Sabico, G.P. Chrousos, P.G. Mcternan, M.K. Piya, "Habitual physical activity is associated with circulating irisin in healthy controls but not in subjects with diabetes mellitus type 2," European Journal of Clinical Investigation, vol. 45, no. 8, pp 775-781, 2015.
• D. Zhu, H. Wang, J. Zhang, X. Zhang, C. Xin, F. Zhang, Y. Lee, L. Zhang, K. Lian, W. Yan, X. Ma, Y. Liu, L. Tao, "Irisin improves endothelial function in type 2 diabetes through reducing oxidative/nitrative stresses," Journal of Molecular and Cellular Cardiology, vol. 87, pp 138-147, 2015.
• T. Kurdiova, M. Balaz, M. Vician, D. Maderova, M. Vlcek, L. Valkovic, M. Srbecky, R. Imrich, O. Kyselovicova, V. Belan, I. Jelok, C. Wolfrum, I. Klimes, M. Krssak, E. Zemkova, D. Gasperikova, J. Ukropec, B. "Ukropcova, Effects of obesity, diabetes and exercise on Fndc5 gene expression and irisin release in human skeletal muscle and adipose tissue: In vivo and in vitro studies," Journal of Physiology, vol. 592, no. 5, pp 1091-1107, 2014.
• S. Pourmoradian, R. Mahdavi, M. Mobasseri, E. Faramarzi, M. Mobasseri, "Effects of royal jelly supplementation on glycemic control and oxidative stress factors in type 2 diabetic female: A randomized clinical trial," Chinese Journal of Integrative Medicine, vol. 20, pp 347-352, 2014.
• P. Irandoost, N. Mesri Alamdari, A. Saidpour, F. Shidfar, N. Roshanravan, M. Asghari Jafarabadi, F. Farsi, N. Asghari Hanjani, M. Vafa, "The effects of royal jelly and tocotrienol-rich fraction on impaired glycemic control and inflammation through irisin in obese rats," Journal of Food Biochemistry, vol. 44, no. 12, pp 1-10, 2020.